Qiagen has announced the acquisition of Ingenuity Systems, the provider of software solutions aimed at efficiently and accurately analysing and interpreting the biological meaning of genomic data.
Ingenuity, a privately-held US company based in California’s Silicon Valley, has created a knowledge system of biomedical information and analysis solutions for the exploration, interpretation and analysis of complex biological systems.
Technologies such as next-generation sequencing are now generating more data in a single year than was created in all prior history, making the analysis and interpretation of this extensive and very complex biological data a critical success factor.
Ingenuity says the foundation of its product portfolio is the Ingenuity Knowledge Base, a 14-year effort to accurately, manually curate, model and computationally structure the vast amount of biomedical literature, including genomic variations implicated in human disease and thousands of disease models.
The Knowledge Base and associated software applications enable users to accurately interpret the meaning of increasingly large amounts of biological data to better guide scientific experiments and medical treatment decisions.
'The interpretation of biological information is becoming a cornerstone of Qiagen’s ecosystem of sample and assay technologies for molecular testing – both in life sciences research and in diagnostics. We are establishing a leading role in this field and intend to further expand the value proposition and scope of our offering,' said Peer Schatz, chief executive officer of Qiagen.
'Ingenuity has created unparalleled leadership with its Knowledge Base, and interpretation solutions to unlock the value of complex genomic and other biological information.'
